Effects of exercise training on markers of adipose tissue remodeling in patients with coronary artery disease and type 2 diabetes mellitus: sub study of the randomized controlled EXCADI trial

Hani Zaidi, Rune Byrkjeland, Ida U Njerve, Sissel Åkra, Svein Solheim, Harald Arnesen, Ingebjørg Seljeflot, Trine B Opstad, Hani Zaidi, Rune Byrkjeland, Ida U Njerve, Sissel Åkra, Svein Solheim, Harald Arnesen, Ingebjørg Seljeflot, Trine B Opstad

Abstract

Background: Investigate effects of long-term exercise on the remodeling markers MMP-9, TIMP-1, EMMPRIN and Galectin-3 in combined type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) patients. Any associations between these biomarkers and glucometabolic variables were further assessed at baseline.

Methods: 137 patients (age 41-81 years, 17.2% females) were included and randomized to a 12-months exercise program or to a control group. Fasting blood samples and subcutaneous adipose tissue (AT) samples were taken at inclusion and after 12-months. The intervention was a combination of aerobic and strength training for a minimum of 150 min per week. Circulating protein levels were measured by ELISA methods and RNA was extracted from AT and circulating leukocytes. Expression levels were relatively quantified by PCR.

Results: After 12 months of intervention, both AT-expression and circulating levels of EMMPRIN were increased in the exercise group (p < 0.05, both) with significant difference in change between the two groups (p < 0.05 both). No significant effect was observed on MMP-9, TIMP-1 and Galectin-3. Levels of TIMP-1 (AT-expression and circulating) were significantly correlated to insulin, and HOMA2- after Bonferroni correction (p = 0.001, by 48 performed correlations).

Conclusion: The increase in levels of EMMPRIN after long-term exercise training, might indicate some degree of AT remodeling in these patients after 12-months of exercise, whether beneficial or not. The remodeling markers were to some extent associated with glucometabolic variables in our population with the combined disease.Trial registration clinicaltrials.gov, NCT01232608. Registered 2 November 2010.

Keywords: Adipose-tissue; EMMPRIN; Exercise; Galectin-3; MMP-9; Remodeling; TIMP-1.

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

© The Author(s) 2019.

References

    1. Kumari M, Heeren J, Scheja L. Regulation of immunometabolism in adipose tissue. Semin Immunopathol. 2018;40:189–202. doi: 10.1007/s00281-017-0668-3.
    1. Itoh M, Suganami T, Hachiya R, et al. Adipose tissue remodeling as homeostatic inflammation. Int J Inflam. 2011;2011:720926. doi: 10.4061/2011/720926.
    1. Tanaka M, Itoh M, Ogawa Y, et al. Molecular mechanism of obesity-induced ‘metabolic’ tissue remodeling. J Diabetes Investig. 2018;9:256–261. doi: 10.1111/jdi.12769.
    1. Visse R, Nagase H, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–573. doi: 10.1016/j.cardiores.2005.12.002.
    1. Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda, Md) 2013;28:391–403. doi: 10.1152/physiol.00029.2013.
    1. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31:40–47. doi: 10.1161/01.STR.31.1.40.
    1. Yu AP, Tam BT, Yau WY, et al. Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults. Diabetol Metab Syndr. 2015;7:111. doi: 10.1186/s13098-015-0108-2.
    1. Laimer M, Kaser S, Kranebitter M, et al. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes. 2005;2005(29):498–501. doi: 10.1038/sj.ijo.0802897.
    1. Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014;71:659–672. doi: 10.1007/s00018-013-1457-3.
    1. Lindsey ML, Yabluchanskiy A, Ma Y. Tissue inhibitor of metalloproteinase-1: actions beyond matrix metalloproteinase inhibition. Cardiology. 2015;132:147–150. doi: 10.1159/000433419.
    1. Opstad TB, Seljeflot I, Bohmer E, et al. MMP-9 and its regulators TIMP-1 and EMMPRIN in patients with acute ST-elevation myocardial infarction: a NORDISTEMI substudy. Cardiology. 2018;139:17–24. doi: 10.1159/000481684.
    1. Mishra B, Kizaki K, Sato T, et al. The role of extracellular matrix metalloproteinase inducer (EMMPRIN) in the regulation of bovine endometrial cell functions. Biol Reprod. 2012;87:149. doi: 10.1095/biolreprod.112.102152.
    1. von Ungern-Sternberg SNI, Zernecke A, Seizer P. Extracellular matrix metalloproteinase inducer EMMPRIN (CD147) in cardiovascular disease. Int J Mol Sci. 2018;19:507. doi: 10.3390/ijms19020507.
    1. Huet E, Gabison EE, Mourah S, et al. Role of emmprin/CD147 in tissue remodeling. Connect Tissue Res. 2008;49:175–179. doi: 10.1080/03008200802151722.
    1. Wang C, Jin R, Zhu X, et al. Function of CD147 in atherosclerosis and atherothrombosis. J Cardiovasc Translation Res. 2015;8:59–66. doi: 10.1007/s12265-015-9608-6.
    1. Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351:336–343. doi: 10.1124/jpet.114.218370.
    1. Weigert J, Neumeier M, Wanninger J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95:1404–1411. doi: 10.1210/jc.2009-1619.
    1. Rhodes DH, Pini M, Castellanos KJ, et al. Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obesity (Silver Spring, Md) 2013;21:310–319. doi: 10.1002/oby.20016.
    1. Martinez-Martinez E, Calvier L, Rossignol P, et al. Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes. 2005;2016(40):1034–1038. doi: 10.1038/ijo.2016.19.
    1. Agarwal SK. Cardiovascular benefits of exercise. Int J Gen Med. 2012;5:541–545. doi: 10.2147/IJGM.S30113.
    1. Kolahdouzi S, Talebi-Garakani E, Hamidian G, et al. Exercise training prevents high-fat diet-induced adipose tissue remodeling by promoting capillary density and macrophage polarization. Life Sci. 2019;220:32–43. doi: 10.1016/j.lfs.2019.01.037.
    1. Jaoude J, Koh Y. Matrix metalloproteinases in exercise and obesity. Vasc Health Risk Manag. 2016;12:287–295. doi: 10.2147/vhrm.s103877.
    1. Nascimento Dda C, Durigan Rde C, Tibana RA, et al. The response of matrix metalloproteinase-9 and -2 to exercise. Sports Med. 2015;45:269–278. doi: 10.1007/s40279-014-0265-8.
    1. Lo Presti R, Hopps E, Caimi G. Gelatinases and physical exercise: a systematic review of evidence from human studies. Medicine. 2017;96:e8072. doi: 10.1097/MD.0000000000008072.
    1. Byrkjeland R, Njerve IU, Anderssen S, et al. Effects of exercise training on HbA1c and VO2 peak in patients with type 2 diabetes and coronary artery disease: a randomised clinical trial. Diabetes Vasc Dis Res. 2015;12:325–333. doi: 10.1177/1479164115590552.
    1. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262.
    1. Reddy VS, Prabhu SD, Mummidi S, et al. Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol. 2010;299:H1242–H1254. doi: 10.1152/ajpheart.00451.2010.
    1. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944–1949. doi: 10.1161/01.CIR.102.16.1944.
    1. Pennings GJ, Yong AS, Kritharides L. Expression of EMMPRIN (CD147) on circulating platelets in vivo. J Thromb Haemo. 2010;8:472–481. doi: 10.1111/j.1538-7836.2009.03716.x.
    1. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011;24:905–913. doi: 10.1177/039463201102400409.
    1. Moghadasi M. Effect of 8 weeks regular endurance training on galectin-3 changes after a strenuous aerobic exercise. J Phys Act Hormones. 2017;1:29–38.
    1. Singh VP, Bali A, Singh N, et al. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14. doi: 10.4196/kjpp.2014.18.1.1.
    1. Matulewicz N, Stefanowicz M, Nikolajuk A, et al. Markers of adipogenesis, but not inflammation, in adipose tissue are independently related to insulin sensitivity. J Clin Endocrinol Metab. 2017;102:3040–3049. doi: 10.1210/jc.2017-00597.
    1. Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34:1228–1237. doi: 10.2337/dc10-1881.
    1. Gielen S, Laughlin MH, O’Conner C, et al. Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations. Prog Cardiovasc Dis. 2015;57:347–355. doi: 10.1016/j.pcad.2014.10.001.
    1. Johnson JL. Metalloproteinases in atherosclerosis. Eur J Pharmacol. 2017;816:93–106. doi: 10.1016/j.ejphar.2017.09.007.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅